Investor Presentation

National Stock Exchange of India Ltd. Exchange Plaza, C 1, Block G, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051. Company Symbol: QMSMEDI ISIN: INE0FMW01018 Ref: QMS MEDICAL ALLIED SERVICES LIMITED Sub: Announcement under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Ma’am, This is with reference to our earlier intimation submitted today pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, we enclose herewith the Investor Presentation released by the Company. It has come to our attention that there were typographical errors in Slide No. 19 and 20 of the Investor presentation, however the same has been rectified. We confirm that there are no changes in other financial numbers reported in the investor presentation for the quarter ended June 30, 2026. We regret the typographical errors and have taken necessary steps to prevent their recurrence in the future Accordingly, the revised Investor Presentation is enclosed herewith for your information and records. Further, pursuant to Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements), 2015, the aforesaid information will also be available on the website of the Company i.e. https://qmsmas.com/. The above information and attachment are for your record and reference. Thanking you, Yours truly, FOR QMS MEDICAL ALLIED SERVICES LIMITED TORAL BHADRA COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO.: A56927 DATE: AUGUST 17, 2026 PLACE: MUMBAI CIN: L33309MH2017PLC299748; Email Id: mm@qmsmas.com QMS Medical Allied Services Ltd Trusted partner for Medical Services & Patient Journey Programs Investor Presentation – Q1FY27 Disclaimer This presentation and the accompanying slides (the “Presentation”), has been prepared by QMS Medical Allied Services Ltd (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward- looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. The Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed. Table of Contents 1 2 3 Q1FY27 Highlights Company Our Overview Offerings Opportunity Annual Landscape Financials Q1FY27 Highlights Management Commentary Q1FY27 marks a strong start to the year for QMS Medical Allied Services, reflecting the strength of our integrated healthcare business model and the investments made over the past year. We delivered revenue of Rs. 56.9 crore, growing 22% YoY, while EBITDA increased 27% YoY to Rs. 8.3 crore, with EBITDA margins improving to 14.6%. PAT stood at Rs. 4 crore, representing a 25% YoY growth. Our Products business continued to demonstrate healthy traction, supported by our expanding distribution network, Q-Devices portfolio and presence across QMSMEDS, e-Grameen and other digital platforms. At the same time, our Services business continued to emerge as a key growth engine, driven by deeper pharma partnerships, increasing adoption of Patient Support Programs and the scaling of our healthcare camp operations. We currently hold a 76% stake in Saarathi Healthcare and expect to acquire the balance stake by the end of Q2FY27. This will further strengthen our capabilities in disease management and Patient Support Programs, enabling us to address the entire patient journey more comprehensively. During the quarter, we also conducted 11,497 B2B health camps, demonstrating our growing execution capabilities and reach. Mahesh Makhija As we move forward, our focus remains on scaling Patient Support Programs, strengthening strategic Founder, Chairman and Managing Director partnerships, expanding Q-Devices and Point-of-Care offerings, and leveraging our technology platform to deliver more integrated and scalable healthcare solutions. We remain confident that our growing capabilities, strong customer relationships and expanding presence across the healthcare ecosystem position QMS well for sustainable growth and long-term value creation. Consolidated Financial Performance – Q1FY27 Revenue from Operations (Rs Cr) EBITDA (Rs Cr) & EBITDA Margin (%) PAT (Rs Cr) & PAT Margin (%) Segment Revenue Mix (%) Q1FY27 14.1% 14.6% 6.8% 7.0% 22% 27% 25% 41% 56.9 Q1FY26 46.5 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Product Services Consolidated Profit & Loss Highlights Particulars (Rs Cr) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q Net Revenue from Operations 56.9 46.5 22% 44.4 28% COGS 26.2 25.9 22.3 Employee Expenses 11.2 3.2 5.7 Other Expenses 11.2 10.8 10.5 EBITDA 8.3 6.5 27% 5.9 41% EBITDA Margin (%) 14.6% 14.1% 13.3% Other Income 0.4 0.3 0.2 Finance Cost 1.7 1.4 2.1 Depreciation 1.5 0.9 1.4 PBT 5.5 4.5 24% 2.7 108% Taxes 1.6 1.3 0.8 PAT 4.0 3.2 25% 1.9 110% PAT Margin (%) 7.0% 6.8% 4.2% EPS (Rs) 2.05 2.20 0.97 Standalone Profit & Loss Highlights Particulars (Rs Cr) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q Net Revenue from Operations 52.3 42.3 24% 39.2 34% COGS 25.5 25.4 22.0 Employee Expenses 10.6 2.7 5.2 Other Expenses 9.3 7.9 7.7 EBITDA 7.0 6.3 11% 4.4 60% EBITDA Margin (%) 13.4% 15.0% 11.2% Other Income 0.2 0.2 0.1 Finance Cost 2.0 1.8 2.4 Depreciation 1.3 0.8 1.2 PBT 3.9 3.9 0.4% 0.9 352% Taxes 1.2 1.2 0.2 PAT 2.7 2.7 -0.3% 0.6 326% PAT Margin (%) 5.1% 6.3% 1.6% EPS (Rs) 1.38 1.48 0.32 Company Overview QMS – A Key Player in Integrated Healthcare Ecosystem Founded in 1994, QMS has grown from a pharma marketing solutions provider into a trusted healthcare partner. QMS MAS is a leading distributor and marketer of a diverse range of [Showing first 8,000 characters — download PDF for full document]